This company has been marked as potentially delisted and may not be actively trading. NASDAQ:EDGE Edge Therapeutics (EDGE) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock About Edge Therapeutics Stock (NASDAQ:EDGE) 30 days 90 days 365 days Advanced Chart Get Edge Therapeutics alerts:Sign Up Key Stats Today's Range$40.15▼$40.1550-Day Range$0.50▼$6.7152-Week Range$0.28▼$17.38Volume34 shsAverage Volume373,201 shsMarket Capitalization$1.27 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ. Read More Receive EDGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edge Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address EDGE Stock News HeadlinesVerve Therapeutics, Inc. (VERV): A Bull Case TheoryJuly 11 at 11:55 AM | msn.come-therapeutics De-risks Clinical Path for GalOmic Candidate ETX-312 with Positive Non-clinical DataJuly 10 at 8:13 AM | tmcnet.comPresident Trump’s Project MAFAPresident Trump’s Boldest Initiative Yet First came “Make America Great Again” (MAGA)… Then came “Make America Healthy Again” (MAHA)… Now comes President Trump’s boldest initiative yet. After a gathering in D.C. with some of the most powerful people in the world, Jeff Brown is now revealing the full details on “Project MAFA.” It’s a revolutionary plan to return America to an era of sound money, eliminate our looming debt disaster, kick off a Golden Century, and more – by July 25. Already, it’s helping small plays jump as high as 300%, 318%, 520%, and even 600%. Jeff Brown is sharing the details Wednesday, July 16, at 8 p.m. ET – including the name of a stock set to profit.July 13 at 2:00 AM | Brownstone Research (Ad)Responding To Bungie’s Comments On My ‘Destiny 2’ Edge Of Fate ArticleJuly 4, 2025 | forbes.comCraniUS Therapeutics Awarded Maryland Tech Council's "2025 Emerging Life Sciences Company of the Year"May 29, 2025 | finance.yahoo.comBiogen and City Therapeutics to develop RNAi therapyMay 28, 2025 | msn.comSunflower Therapeutics Announces the First System Delivery and Installation of the Daisy Petal™ Perfusion Bioreactor System to BioBuilderMay 20, 2025 | finance.yahoo.comIntegra Therapeutics announces new pre-clinical data at 28th Annual Meeting of American Society of Gene and Cell Therapy (ASGCT)May 14, 2025 | finance.yahoo.comSee More Headlines EDGE Stock Analysis - Frequently Asked Questions How were Edge Therapeutics' earnings last quarter? Edge Therapeutics, Inc. (NASDAQ:EDGE) released its quarterly earnings results on Thursday, November, 1st. The biotechnology company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.27) by $0.16. What other stocks do shareholders of Edge Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Edge Therapeutics investors own include ContraFect (CFRX), McEwen Mining (MUX), Arena Pharmaceuticals (ARNA), BioLineRx (BLRX), Bristol Myers Squibb (BMY), Cerecor (CERC) and CRISPR Therapeutics (CRSP). Company Calendar Last Earnings11/01/2018Today7/13/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:EDGE CIK1472091 Webwww.edgetherapeutics.com Phone(800) 208-3343FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$40.86 million Net MarginsN/A Pretax MarginN/A Return on Equity-81.29% Return on Assets-56.92% Debt Debt-to-Equity RatioN/A Current Ratio5.59 Quick Ratio5.59 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.95 per share Price / Book42.26Miscellaneous Outstanding Shares31,510,000Free FloatN/AMarket Cap$1.27 billion OptionableNot Optionable Beta3.65 The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:EDGE) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edge Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edge Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EDGE Stock Alerts